AWM
LUMO

Apollon Wealth Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Apollon Wealth Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-188
Closed -$3K – 716
2020
Q2 		$3K Buy
+188
New +$2.24K ﹤0.01% 618

Other funds holding LUMO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Apollon Wealth Management's LUMO Position: Q3 2020 in Review

Apollon Wealth Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2020, closing a stake of 188 shares — an estimated $3K sold.

Apollon Wealth Management first reported a position in LUMO in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 38 funds tracked by Wall St. Rank hold LUMO as of Q3 2020.

  • Apollon Wealth Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Apollon Wealth Management sold 188 Lumos Pharma, Inc. Common Stock shares in Q3 2020, an estimated $3K.
  • Apollon Wealth Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Apollon Wealth Management's Lumos Pharma, Inc. Common Stock position peaked at $3K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2020.

Based on Apollon Wealth Management's 13F filing for Q3 2020, filed 3 Nov 2020.